City of Hope's Dr. Yuman Fong Delivers Lister Legacy Lecture, Spotlighting Surgical Cancer Innovations
LOS ANGELES--(BUSINESS WIRE)-- Yuman Fong, M.D., chair of the Department of Surgery at City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report, this month delivered the Lister Legacy Lecture at the triennial conference of The Royal College of Surgeons of Edinburgh. This presentation honors the long-term impact of Baron Joseph Lister, M.D., who brought antiseptic techniques and many other innovations to surgery, saving more lives and making a real difference in how patients live.
'I am humbled to have been asked to speak on 'The Surgeon in the 21st Century.' Sir Joseph Lister's work with antiseptics laid the foundation for the sterile surgical practices we rely on today. His forward-looking mindset has inspired me to collaborate with doctors and med-tech companies around the world to push the boundaries of surgical innovation.
'At City of Hope, we are exploring the use of AI and robotics in research settings to make it one day possible for specialists to perform remote surgery together. The goal is to make exceptional cancer surgery available to everyone — no matter where they live or how close they are to a major cancer center,' said Dr. Fong, City of Hope's Sangiacomo Family Chair in Surgical Oncology.
The Royal College of Surgeons of Edinburgh is one of the oldest surgical colleges in the world and is where the father of modern surgery, Dr. Joseph Lister, worked for much of his career as a general surgeon, pathologist and medical scientist. Before Dr. Lister's pioneering work in antiseptics, people were just about ready to give up on surgery altogether because infections were killing so many patients. Dr. Lister is still on people's lips today; the popular mouthwash Listerine was named in honor of him.
Dr. Fong Is Curing Stage 4 Colorectal Cancer
Metastatic colorectal cancer that has spread to the liver was once considered incurable. Dr. Fong is known internationally for his expertise in liver surgery and for proving that liver resection sometimes can cure Stage 4 colorectal cancer. In fact, he devised a new scoring system called the Fong Score that is widely used in staging for this population of patients, allowing surgeons to plan a path toward surgical cure.
Along the journey to less invasive liver therapies, Dr. Fong has contributed to the design and deployment of many new minimally invasive surgical and interventional tools that are used worldwide. More recently, Dr. Fong led a team that demonstrated robotic liver surgery can safely and routinely be performed as outpatient surgery.
The Next Generation of Gene Therapy
Dr. Fong has focused on gene therapy for over two decades, engineering viruses and immune cells to kill cancer. His City of Hope team developed CF33, a cancer-fighting virus that has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumors in preclinical laboratory and animal models.
Importantly, CF33 wakes up the immune system to join the fight. There are many ongoing multisite clinical trials to evaluate the safety and efficacy of investigational solid and blood cancer therapies based on Dr. Fong's CF33 technology*.
Leveraging AI and Wearables to Improve Patient Outcomes
Immunotherapies are making more cancers that were previously inoperable operatable. Minimally invasive robotic surgery has turned surgeons into superheroes with computer-aided vision sometimes powered by augmented reality (AR) for a clearer, more interactive view of what's happening inside the body. AR is enabling remote surgery and multispecialty collaboration where surgeons in different locations can work together in real time guided by shared visualizations and data overlays. Remote surgery is still undergoing preclinical testing, though it promises to be a powerful tool in emergency settings when access to top specialists is limited.
AI-guided robotic systems are being tested as assistants in complex cancer surgery that can one day decrease the risk of surgical complications. For example, AI could predict how tissue will move and designate 'no go zones' where snips should not occur. In the future, some simple surgical tasks can be automated under the supervision of experienced surgeons, increasing patient safety as well as improving working conditions for surgeons who often have long operating room schedules.
Additionally, Dr. Fong and his team are testing how wearables or remote monitoring devices can be leveraged before and after surgery to improve patient outcomes. For example, City of Hope has a $7 million funding award from the Patient-Centered Outcomes Research Institute (PCORI) to study how physical activity before and after surgery affects recovery in an older patient population.
'City of Hope is fast-tracking promising laboratory research into clinical trials. We incubate the next generation of cancer therapies on our campuses in Los Angeles and Orange County and look forward to one day offering these innovative investigational therapies to patients who come to our nationwide locations in Arizona, Illinois and Georgia and beyond,' Dr. Fong said.
* City of Hope exclusively licensed patent rights covering CF33 to Imugene Limited. Dr. Fong has the rights to commercialization revenue from the company and is a paid member of Imugene Limited's scientific advisory board.
About City of Hope
City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report at its core, City of Hope's uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope's growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope's affiliated group of organizations includes Translational Genomics Research Institute and AccessHope TM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
Bay Psychiatric Associates Hosts Open House for Healthcare Providers
SAN MATEO, Calif.--(BUSINESS WIRE)--Bay Psychiatric Associates is excited to announce a successful Open House event at its newly expanded San Mateo location, held on Wednesday, May 7th, 2025. This event welcomed healthcare providers interested in learning more about the clinic's comprehensive mental health services, including Ketamine/Spravato, Transcranial Magnetic Stimulation (TMS), and Outpatient Services such as Psychotherapy and Medication Management. We're thrilled to open our doors to healthcare providers in the community and share the innovative treatments we offer to help individuals manage mental health conditions. Share Founded in 1994, Bay Psychiatric Associates has long been a trusted leader in mental health care in the Bay Area. To meet the growing demand for advanced treatment options, the clinic has expanded its services. The multidisciplinary team, including psychiatrists and dedicated support staff, works collaboratively to ensure patients receive effective, accessible, and compassionate care. The Open House featured guided tours of the facility, opportunities to meet the clinic's medical and administrative staff, and an in-depth overview of the latest in psychiatric care. Hors d'oeuvres and refreshments were provided, and the event also served as a networking opportunity for local healthcare professionals to connect and discuss potential referral partnerships. 'We're thrilled to open our doors to healthcare providers in the community and share the innovative treatments we offer to help individuals manage mental health conditions,' said Dr. Roberto Estrada, Interventional Psychiatry Medical Director at Bay Psychiatric Associates. 'Our team has worked tirelessly to ensure that our services are not only effective but also accessible to those who need them most. We look forward to discussing these advancements with our colleagues in the healthcare field.' About Bay Psychiatric Associates Bay Psychiatric Associates is a leading mental health provider in the Bay Area, specializing in innovative treatments for mental health conditions, including Transcranial Magnetic Stimulation (TMS), Spravato (esketamine), and ketamine therapy. The clinic's multidisciplinary team is dedicated to providing the highest quality care to patients struggling with depression, anxiety, and other mental health disorders. Outpatient clinics are located in Berkeley, San Francisco, Corte Madera, and San Mateo. Learn more via our website.
Business Wire
9 hours ago
- Business Wire
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced details of Embolden™, the Company's registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older. The Company has written agreement from the U.S. Food and Drug Administration (FDA) on key aspects of the registrational trial's design. 'We appreciate the partnership with the FDA as we aligned on the key elements of our NGN-401 registrational trial design, which will allow for rapid conversion of the current Phase 1/2 study to a pivotal trial,' said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. 'We believe that the robust endpoint design, which was informed by key opinion leaders, caregiver input and primary market research with payors, will support NGN-401's best-in-class potential and provide key differentiating data critical to the Rett syndrome community and the future commercial success of NGN-401.' 'I appreciate the multi-domain approach across the clinical manifestations of Rett syndrome, and rigor in which the primary endpoint will be evaluated, including both the clinician perspective of improvement using the CGI-I scale with Rett syndrome anchors and videos to demonstrate gains of skills that are clinically meaningful for girls and women with Rett syndrome and their families,' said Elizabeth M. Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological Sciences and Biochemistry at Rush University, and principal investigator in the NGN-401 clinical trial. 'Participants treated with NGN-401 have demonstrated increased independence, with both fine and gross motor function improvement, and gained the ability to better communicate wants, needs and choices. I have been impressed with the improvements observed in participants after NGN-401 administration, which have included global improvement in signs and symptoms of Rett syndrome and gains of multi-domain developmental milestones that would not be expected to occur spontaneously in the post-regression stage of Rett syndrome. Evaluating treatment effect in participants ages 3 and above in the registrational study will provide important insights on the potential benefits of NGN-401 in younger patients early in the course of this progressive disease.' Obtained Written Agreement from FDA on the Following Key Elements of Embolden Registrational Trial Design After Discussions Under the START Program Study Design: Open-label, single arm, baseline control (i.e., participants serving as their own control); N=18 proposed, subject to feedback from the FDA. Patient Population: Females ages ≥ 3 years with Rett syndrome, which is consistent with Neurogene's analysis of the NIH-sponsored, International Rett Syndrome Foundation (IRSF) Rett syndrome natural history study that shows patients ages 3 and above rarely learn new skills/reach developmental milestones or relearn skills once lost. The FDA's written agreement endorsed the Company's analysis. Dose: 1E15 vector genomes (vg). Primary Endpoint: Responder-based composite endpoint that will assess an improvement in the Clinical Global Impression-Improvement (CGI-I) scale with Rett syndrome anchors and the gain of a developmental milestone/skill, compared to a participant's own baseline. Responders are defined as participants who: Attain a CGI-I score of ≤ 3 ('minimally improved'); and Gain any one developmental milestone/skill from a list of 28, as captured through standardized video recordings and independently verified by blinded central raters. Developmental milestones/skills were informed by a Rett syndrome caregiver survey, provided to the FDA, demonstrating that the acquisition of any single skill within the selected set is considered clinically meaningful. The primary endpoint will be evaluated at 12 months following NGN-401 administration, with feedback pending from the FDA to consider the addition of a 6-month endpoint. Neurogene has begun registrational trial initiation activities. 'It has been incredibly rewarding to see how RSRT's early investments in foundational Rett syndrome science helped lay the groundwork for what's now a promising gene therapy program approaching a registrational trial,' said Monica Coenraads, Founder and Chief Executive Officer of RSRT. 'RSRT has been a long-time champion of addressing the underlying genetic cause of Rett syndrome and Neurogene's program has the potential to do just that. We appreciate the thoughtful design of the trial that importantly incorporates the caregiver perspective on what meaningful improvement may look like. We congratulate the Neurogene team on reaching alignment with the FDA and thank the Rett community at large for their support in advancing this program. The future is bright!' 'Our partnership with Neurogene reflects a shared commitment to accelerating meaningful treatments for Rett syndrome,' said Laura Hameed, Chief Executive Officer of the International Rett Syndrome Foundation (IRSF). 'The use of IRSF's Natural History Study data to support the NGN-401 gene therapy registrational trial design is a powerful example of how families accelerate and streamline therapeutic development. We are grateful to the families that contributed to the NHS, and to the families participating in this trial whose time and commitment are essential to evaluating gene therapy for Rett syndrome.' Phase 1/2 Trial Data Support Registrational Trial Design Previously disclosed clinical data from the Phase 1/2 study* support the registrational trial design. Data showed improvements in Rett syndrome assessments with an aggregate of 23 developmental milestones/skills acquired in the first four participants. Specifically, the four participants: Each achieved a clinically meaningful rating of 2, or 'much improved,' on the CGI-I; and Collectively achieved 23 developmental milestones/skills in the core clinical domains of Rett syndrome – hand function/fine motor, communication/language, and ambulation/gross motor, including: Participant 1 gained 10 skills across multiple domains by 15 months post-dose; Participant 2 gained 8 skills across multiple domains by 12 months post-dose; Participant 3 gained 3 skills across multiple domains by 9 months post-dose; and Participant 4 gained 2 skills by 3 months post-dose. *Efficacy data from the first four participants; as of data cut-off date of October 17, 2024 Phase 1/2 Trial Enrollment and Update Neurogene previously shared that five additional participants had been dosed in the Phase 1/2 portion of the NGN-401 clinical trial during the first half of 2025. A total of 10 participants have received the 1E15 vg dose. There has been no evidence of hemophagocytic lymphohistiocytosis (HLH) / hyperinflammatory syndrome in any participant at the 1E15 vg dose level. Neurogene remains on track to share updated clinical efficacy and safety data in the second half of 2025. Cash Runway Update As of March 31, 2025, Neurogene had cash, cash equivalents, and investments of $292.6 million. The Company's current budget reflects a reallocation of capital from pipeline development to support pivotal trial activities for NGN-401. Neurogene now expects its existing resources will be sufficient to fund operations into early 2028. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit About NGN-401 NGN-401 is an investigational AAV9 gene therapy being developed as a one-time treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT™ transgene regulation technology. EXACT technology is an important advancement in gene therapy for Rett syndrome, specifically because the disorder requires a treatment approach that enables targeted levels of MECP2 transgene expression without causing overexpression-related toxic effects associated with conventional gene therapy. NGN-401 was selected by the U.S. Food and Drug Administration (FDA) for its START Pilot Program and has also received Regenerative Medicine Advance Therapy (RMAT) designation, orphan drug designation, Fast Track designation and rare pediatric designation from the FDA. Neurogene was previously granted an INTERACT meeting with the FDA regarding the EXACT technology. NGN-401 also received Priority Medicines (PRIME) designation, orphan designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) and the Innovative Licensing and Application Pathway (ILAP) designation from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Cautionary Note Regarding Forward-Looking Statements Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: trial designs, clinical development plans and timing for NGN-401, including elements of the registrational clinical study trial design subject to final approval of the FDA, such as the proposed number of participants in the Embolden trial and the addition of a six month endpoint, and timing of the conversion of the NGN-401 Phase 1/2 clinical trial to a registrational clinical trial; expected future interactions with or positions of the FDA; the safety, tolerability and efficacy of NGN-401; the potential for success of the Embolden registrational clinical trial for NGN-401 for the treatment of Rett syndrome; expected timing for additional interim data from the Company's NGN-401 Phase 1/2 trial for Rett Syndrome; the effectiveness of the monitoring and treatment protocol for HLH in Neurogene's Phase 1/2 clinical trial of NGN-401; and the time period over which existing cash resources may be sufficient to fund the Company's operations. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' 'on track,' and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene's control. Such risks, uncertainties and assumptions include, among other things, uncertainties regarding interactions with and feedback received from the FDA staff responsible for approving the design of our registrational trial and the risks and uncertainties identified under the heading "Risk Factors" included in Neurogene's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on March 24, 2025, Neurogene's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 9, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Business Wire
9 hours ago
- Business Wire
HCA Healthcare, Inc. 2nd Quarter 2025 Earnings Conference Call
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) announces the following Webcast: Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, If you are unable to listen during the live webcast, the call will be archived on the web site:
